State Street Corp's Strategic Acquisition in Vir Biotechnology Inc
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
We're Keeping An Eye On Vir Biotechnology's (NASDAQ:VIR) Cash Burn Rate
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta And Hepatitis B Programs At AASLD's The Liver Meeting 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Executive Reshuffles: LLY, S and RY Companies in Focus
Vir Biotechnology Enhances Portfolio With Sanofi Deal and Executive Appointments
Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer
Express News | Vir Biotechnology Appoints Jason O’byrne as Chief Financial Officer
Sanofi Shares Are Trading Lower After Vir Biotechnology Announced the Closing of an Exclusive License Agreement With the Company.
Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High...
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
Vir Biotechnology Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
Gate Bioscience Appoints Industry Veteran Jeff Hatfield to Board of Directors
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target